Why Is AT&T Stock Dropping?
The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…
Buy
64
ATHE Quote, Financials, Valuation and Earnings
Last price:
$3.39
Seasonality move
:
-7.31%
Day range:
$3.32 - $3.45
52-week range:
$1.00 - $4.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.50x
P/B ratio:
3.24x
Volume:
17.1K
Avg. volume:
91K
1-year change:
80.95%
Market cap:
$29.9M
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ATHE
Alterity Therapeutics
|
-- | -- | -- | -- | $9.00 |
|
IMMP
Immutep
|
-- | -- | -- | -- | -- |
|
IMRN
Immuron
|
-- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics
|
-- | -- | -- | -- | -- |
|
MESO
Mesoblast
|
$4.6M | -- | -100% | -- | $11.00 |
|
OPT
Opthea
|
-- | -- | -- | -- | $12.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ATHE
Alterity Therapeutics
|
$3.42 | $9.00 | $29.9M | -- | $0.00 | 0% | 1.50x |
|
IMMP
Immutep
|
$1.93 | -- | $280.7M | -- | $0.00 | 0% | -- |
|
IMRN
Immuron
|
$2.15 | -- | $12.3M | -- | $0.00 | 0% | 3.81x |
|
KZIA
Kazia Therapeutics
|
$1.42 | -- | $6.2M | -- | $0.00 | 0% | -- |
|
MESO
Mesoblast
|
$17.30 | $11.00 | $2B | -- | $0.00 | 0% | 179.39x |
|
OPT
Opthea
|
$3.90 | $12.17 | $599.4M | -- | $0.00 | 0% | 2,492.46x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ATHE
Alterity Therapeutics
|
-- | -4.982 | -- | -- |
|
IMMP
Immutep
|
-- | -0.152 | -- | -- |
|
IMRN
Immuron
|
-- | 2.703 | -- | 4.83x |
|
KZIA
Kazia Therapeutics
|
-6.76% | 0.052 | 5.57% | 0.07x |
|
MESO
Mesoblast
|
-- | -0.629 | -- | -- |
|
OPT
Opthea
|
215.31% | 0.522 | 53.76% | 2.88x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ATHE
Alterity Therapeutics
|
-- | -- | -- | -- | -- | -- |
|
IMMP
Immutep
|
-- | -- | -- | -- | -- | -- |
|
IMRN
Immuron
|
-- | -- | -40.9% | -40.9% | -- | -- |
|
KZIA
Kazia Therapeutics
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
MESO
Mesoblast
|
-- | -- | -- | -- | -- | -- |
|
OPT
Opthea
|
-- | -- | -669.85% | -- | -- | -- |
Alterity Therapeutics vs. Competitors
-
Which has Higher Returns ATHE or IMMP?
Immutep has a net margin of -- compared to Alterity Therapeutics's net margin of --. Alterity Therapeutics's return on equity of -- beat Immutep's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATHEAlterity Therapeutics-- -- -- IMMPImmutep-- -- -- -
What do Analysts Say About ATHE or IMMP?
Alterity Therapeutics has a consensus price target of $9.00, signalling upside risk potential of 163.16%. On the other hand Immutep has an analysts' consensus of -- which suggests that it could grow by 392.23%. Given that Immutep has higher upside potential than Alterity Therapeutics, analysts believe Immutep is more attractive than Alterity Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings ATHEAlterity Therapeutics1 0 0 IMMPImmutep2 0 0 -
Is ATHE or IMMP More Risky?
Alterity Therapeutics has a beta of 0.655, which suggesting that the stock is 34.451% less volatile than S&P 500. In comparison Immutep has a beta of 2.197, suggesting its more volatile than the S&P 500 by 119.655%.
-
Which is a Better Dividend Stock ATHE or IMMP?
Alterity Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immutep offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alterity Therapeutics pays -- of its earnings as a dividend. Immutep pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATHE or IMMP?
Alterity Therapeutics quarterly revenues are --, which are smaller than Immutep quarterly revenues of --. Alterity Therapeutics's net income of -- is lower than Immutep's net income of --. Notably, Alterity Therapeutics's price-to-earnings ratio is -- while Immutep's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alterity Therapeutics is 1.50x versus -- for Immutep. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATHEAlterity Therapeutics1.50x -- -- -- IMMPImmutep-- -- -- --
-
Which has Higher Returns ATHE or IMRN?
Immuron has a net margin of -- compared to Alterity Therapeutics's net margin of --. Alterity Therapeutics's return on equity of -- beat Immuron's return on equity of -40.9%.
Company Gross Margin Earnings Per Share Invested Capital ATHEAlterity Therapeutics-- -- -- IMRNImmuron-- -- $8.5M -
What do Analysts Say About ATHE or IMRN?
Alterity Therapeutics has a consensus price target of $9.00, signalling upside risk potential of 163.16%. On the other hand Immuron has an analysts' consensus of -- which suggests that it could grow by 132.59%. Given that Alterity Therapeutics has higher upside potential than Immuron, analysts believe Alterity Therapeutics is more attractive than Immuron.
Company Buy Ratings Hold Ratings Sell Ratings ATHEAlterity Therapeutics1 0 0 IMRNImmuron0 0 0 -
Is ATHE or IMRN More Risky?
Alterity Therapeutics has a beta of 0.655, which suggesting that the stock is 34.451% less volatile than S&P 500. In comparison Immuron has a beta of 1.376, suggesting its more volatile than the S&P 500 by 37.636%.
-
Which is a Better Dividend Stock ATHE or IMRN?
Alterity Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alterity Therapeutics pays -- of its earnings as a dividend. Immuron pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATHE or IMRN?
Alterity Therapeutics quarterly revenues are --, which are smaller than Immuron quarterly revenues of --. Alterity Therapeutics's net income of -- is lower than Immuron's net income of --. Notably, Alterity Therapeutics's price-to-earnings ratio is -- while Immuron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alterity Therapeutics is 1.50x versus 3.81x for Immuron. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATHEAlterity Therapeutics1.50x -- -- -- IMRNImmuron3.81x -- -- --
-
Which has Higher Returns ATHE or KZIA?
Kazia Therapeutics has a net margin of -- compared to Alterity Therapeutics's net margin of --. Alterity Therapeutics's return on equity of -- beat Kazia Therapeutics's return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital ATHEAlterity Therapeutics-- -- -- KZIAKazia Therapeutics-- -- -$6.3M -
What do Analysts Say About ATHE or KZIA?
Alterity Therapeutics has a consensus price target of $9.00, signalling upside risk potential of 163.16%. On the other hand Kazia Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1312.2%. Given that Kazia Therapeutics has higher upside potential than Alterity Therapeutics, analysts believe Kazia Therapeutics is more attractive than Alterity Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings ATHEAlterity Therapeutics1 0 0 KZIAKazia Therapeutics0 0 0 -
Is ATHE or KZIA More Risky?
Alterity Therapeutics has a beta of 0.655, which suggesting that the stock is 34.451% less volatile than S&P 500. In comparison Kazia Therapeutics has a beta of 2.117, suggesting its more volatile than the S&P 500 by 111.748%.
-
Which is a Better Dividend Stock ATHE or KZIA?
Alterity Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kazia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alterity Therapeutics pays -- of its earnings as a dividend. Kazia Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATHE or KZIA?
Alterity Therapeutics quarterly revenues are --, which are smaller than Kazia Therapeutics quarterly revenues of --. Alterity Therapeutics's net income of -- is lower than Kazia Therapeutics's net income of --. Notably, Alterity Therapeutics's price-to-earnings ratio is -- while Kazia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alterity Therapeutics is 1.50x versus -- for Kazia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATHEAlterity Therapeutics1.50x -- -- -- KZIAKazia Therapeutics-- -- -- --
-
Which has Higher Returns ATHE or MESO?
Mesoblast has a net margin of -- compared to Alterity Therapeutics's net margin of --. Alterity Therapeutics's return on equity of -- beat Mesoblast's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATHEAlterity Therapeutics-- -- -- MESOMesoblast-- -- -- -
What do Analysts Say About ATHE or MESO?
Alterity Therapeutics has a consensus price target of $9.00, signalling upside risk potential of 163.16%. On the other hand Mesoblast has an analysts' consensus of $11.00 which suggests that it could grow by 30.06%. Given that Alterity Therapeutics has higher upside potential than Mesoblast, analysts believe Alterity Therapeutics is more attractive than Mesoblast.
Company Buy Ratings Hold Ratings Sell Ratings ATHEAlterity Therapeutics1 0 0 MESOMesoblast0 0 0 -
Is ATHE or MESO More Risky?
Alterity Therapeutics has a beta of 0.655, which suggesting that the stock is 34.451% less volatile than S&P 500. In comparison Mesoblast has a beta of 3.357, suggesting its more volatile than the S&P 500 by 235.658%.
-
Which is a Better Dividend Stock ATHE or MESO?
Alterity Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mesoblast offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alterity Therapeutics pays -- of its earnings as a dividend. Mesoblast pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATHE or MESO?
Alterity Therapeutics quarterly revenues are --, which are smaller than Mesoblast quarterly revenues of --. Alterity Therapeutics's net income of -- is lower than Mesoblast's net income of --. Notably, Alterity Therapeutics's price-to-earnings ratio is -- while Mesoblast's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alterity Therapeutics is 1.50x versus 179.39x for Mesoblast. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATHEAlterity Therapeutics1.50x -- -- -- MESOMesoblast179.39x -- -- --
-
Which has Higher Returns ATHE or OPT?
Opthea has a net margin of -- compared to Alterity Therapeutics's net margin of --. Alterity Therapeutics's return on equity of -- beat Opthea's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATHEAlterity Therapeutics-- -- -- OPTOpthea-- -- $65.7M -
What do Analysts Say About ATHE or OPT?
Alterity Therapeutics has a consensus price target of $9.00, signalling upside risk potential of 163.16%. On the other hand Opthea has an analysts' consensus of $12.17 which suggests that it could grow by 212.37%. Given that Opthea has higher upside potential than Alterity Therapeutics, analysts believe Opthea is more attractive than Alterity Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings ATHEAlterity Therapeutics1 0 0 OPTOpthea5 0 0 -
Is ATHE or OPT More Risky?
Alterity Therapeutics has a beta of 0.655, which suggesting that the stock is 34.451% less volatile than S&P 500. In comparison Opthea has a beta of 0.710, suggesting its less volatile than the S&P 500 by 29.036%.
-
Which is a Better Dividend Stock ATHE or OPT?
Alterity Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Opthea offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alterity Therapeutics pays -- of its earnings as a dividend. Opthea pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATHE or OPT?
Alterity Therapeutics quarterly revenues are --, which are smaller than Opthea quarterly revenues of --. Alterity Therapeutics's net income of -- is lower than Opthea's net income of --. Notably, Alterity Therapeutics's price-to-earnings ratio is -- while Opthea's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alterity Therapeutics is 1.50x versus 2,492.46x for Opthea. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATHEAlterity Therapeutics1.50x -- -- -- OPTOpthea2,492.46x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is American Express Stock Going Lower?
American Express Company (NYSE:AXP) has long been a Buffett favorite…
Cigna vs Costco Stock: Which Is Best?
Cigna and Costco don’t usually go hand in hand but…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
QMCO alert for Jan 18
Quantum [QMCO] is down 15.61% over the past day.
Buy
51
QRVO alert for Jan 18
Qorvo [QRVO] is up 14.47% over the past day.
Sell
31
ATEX alert for Jan 18
Anterix [ATEX] is up 11.14% over the past day.
